Collier B Gladin Jr Md

CLIA Laboratory Citation Details

2
Total Citations
7
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 11D0948963
Address 140 North Crest Boulevard, Macon, GA, 31210
City Macon
State GA
Zip Code31210
Phone478 757-8335
Lab DirectorCOLLIER MD

Citation History (2 surveys)

Survey - February 10, 2021

Survey Type: Standard

Survey Event ID: OT6Y11

Deficiency Tags: D0000 D2009

Summary:

Summary Statement of Deficiencies D0000 A Clinical Laboratory Improvement Amendments (CLIA) Recertification survey was completed on February 10, 2021. The laboratory was not in compliance with applicable CLIA requirements found at 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D2009 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods. This STANDARD is not met as evidenced by: Based on review of the American Proficiency Institute (API) Proficiency Testing (PT) documents, the laboratory failed to obtain the testing personnel (TP), and the Laboratory Director's (LD) signature on the Attestation Statement for all three events for the 2020 Hematology, and second event for 2019 Hematology. Findings: 1. Review of the PT documents from API for all three events for 2020, for Hematology, and the second event for 2019, the attestation statements were not signed by the LD or the TP to attest that the PT samples were analyzed in the same manner as patient samples. 2. Interview with the LD, and the TP, in the laboratory office on February 10, 2021, at approximately 1 pm, confirmed that the Attestation Statements for the Hematology PT, for all three events for 2020 and the second event for 2019, were not signed by the LD or the TP. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - May 22, 2018

Survey Type: Special

Survey Event ID: OKFW11

Deficiency Tags: D0000 D2016 D2130 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 A proficiency testing desk review was completed on May 22, 2018. At the time of the review, the laboratory was not in compliance with the Clinical Laboratory Improvement Amendments of 1988, 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory proficiency testing (PT) performance for automated white blood cell (WBC) differential analyte in 2016 event three, 2017 event two and 2018 event one, resulting in the second unsuccessful occurrence for WBC differential. (Refer to D2130). Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and review of the laboratory's 2016, 2017 and 2018 proficiency testing (PT) evaluation reports, the laboratory failed to maintain satisfactory performance for three of five consecutive proficiency testing events for the automated white blood cell (WBC) differential resulting in the second unsuccessful PT occurrence for WBC differential. The findings include: 1. Review of the CMS 155 revealed the following unsatisfactory automated WBC differential scores: 2016 event three 67%, 2017 event two 73% and 2018 event one 0%. 2. Review of the 2016 event three evaluation report revealed unacceptable scores for Granulocytes % for sample numbers HEM-11 and HEM-14, Lymphocytes % for sample number HEM-11 and Monocyte/Mid% for sample numbers HEM-11 and HEM-14. 3. Review of the 2017 event two evaluation report revealed unacceptable scores for Lymphocytes % for sample number HEM-07 and HEM-10 and Monocyte/Mid% for sample numbers HEM-07 and HEM-10. 4. Review of the 2018 event one evaluation report revealed unacceptable scores for WBC differential for 'Failure to Participate', resulting in the second PT occurrence for WBC differential.. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: The laboratory director failed to maintain compliance with successful white blood cell (WBC) differential proficiency testing (PT) for three of five consecutive events and failed to ensure the laboratory participated in PT on 2018 event one, resulting in the second unsuccessful PT occurrence for WBC differential. (Refer to D6016) D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and the laboratory's 2016, 2017 and 2018 proficiency testing (PT) -- 2 of 3 -- evaluation reports, the laboratory director failed to ensure the laboratory maintained satisfactory performance for three of five consecutive proficiency testing events for the automated white blood cell (WBC) differential resulting in the second unsuccessful PT occurrence for WBC differential. The findings include: 1. Review of the CMS 155 revealed the following unsatisfactory automated WBC differential scores: 2016 event three 67%, 2017 event two 73% and 2018 event one 0%. 2. Review of the 2016 event three evaluation report revealed unacceptable scores for Granulocytes % for sample numbers HEM-11 and HEM-14, Lymphocytes % for sample number HEM-11 and Monocyte/Mid% for sample numbers HEM-11 and HEM-14. 3. Review of the 2017 event two evaluation report revealed unacceptable scores for Lymphocytes % for sample number HEM-07 and HEM-10 and Monocyte /Mid% for sample numbers HEM-07 and HEM-10. 4. Review of the 2018 event one evaluation report revealed unacceptable scores for WBC differential for 'Failure to Participate', resulting in the second PT occurrence for WBC differential. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access